CN103211226A - Application of punicic acid or punicic acid compound in increasing DHA (docosahexaenoic acid) content in vivo - Google Patents
Application of punicic acid or punicic acid compound in increasing DHA (docosahexaenoic acid) content in vivo Download PDFInfo
- Publication number
- CN103211226A CN103211226A CN2013101372986A CN201310137298A CN103211226A CN 103211226 A CN103211226 A CN 103211226A CN 2013101372986 A CN2013101372986 A CN 2013101372986A CN 201310137298 A CN201310137298 A CN 201310137298A CN 103211226 A CN103211226 A CN 103211226A
- Authority
- CN
- China
- Prior art keywords
- acid
- punicic acid
- punicic
- dha
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Abstract
The invention belongs to the fields of food nutriology and clinical nutriology. DHA (docosahexaenoic acid) content in a mammal and human body is increased by mainly applying the punicic acid or the punicic acid compound; the punicic acid compound comprises punicic acid ester, punicic acid salt or punicic acid metabolite; and the punicic acid comprises pomegranate seed oil containing the punicic acid or trchosahthes kirilowii maxin seed oil containing the punicic acid. The punicic acid or punicic acid compound is taken orally.
Description
Technical field
The invention belongs to food science, clinical nutriology field, mainly is the content that application punicic acid or punicic acid compound improve the DHA (DHA) in mammal and the human body.
Background technology
DHA(Docosahexaenoic acid, C22:6n-3), DHA is commonly called as brain gold, is a kind of to the very important polyunsaturated fatty acid of human body, belongs to the important member in the Omega-3 unrighted acid family.DHA is a kind of essential element that nervous system cell is grown and kept, and is brain and amphiblestroid important composition composition, and content is up to 20% in the human brain cortex, proportion maximum in eye retina, account for 50%, therefore, grow most important tire infant intelligence and eyesight.Studies show that the absorption of capacity DHA can reduce postpartum depression; DHA with and derivative can kill multiple cancer cell; DHA can suppress the formation of inflammation precursor, has antiinflammation; Can reduce blood fat fat, prevention cardiovascular and cerebrovascular disease.Studies show that abroad DHA takes in suitable, can reduce the risk of suffering from the Alzheimers senile dementia, and can slow down the decline of the cognitive ability relevant with age growth.Not only to the elderly, DHA keeps the bone density peak value of whole body and vertebra that positive role is also arranged to healthy young man.
At present, the DHA replenishers on the market mainly contain three classes, and a class is fish DHA goods, and second class is the algae DHA goods, and the 3rd class is yolk DHA.But limited to the rising of the DHA content in the body after taking in, therefore the new method of utilizing nutriment to improve DHA in the mammalian body needs research.
Conjugate linolenic acid (Conjugated linolenic acid) is a kind of 18 carbon conjugated triene aliphatic acid, has the physiologically active that is highly profitable, and mainly comprises: anticancer, carcinogenesis, reducing blood lipid, fat-reducing etc.Wherein, conjugate linolenic acid can change a series of functions such as fat metabolism, with and be converted into CLA in vivo (conjugated linoleic acid, 9c 11t-CLA), thereby bring into play more physiological function.Conjugate linolenic acid can by the position difference of two keys (8,10,12-18:3 and 9,11,13-18:3) with geometric configuration different (c, c, c-, the c of two keys, t, c-, c, t, t-etc.) there is different isomers, wherein, punicic acid (punicic acid, punicic acid), also claim trichosanic acid, i.e. 9c, 11t, 13c-18:3 are main a kind of conjugate linolenic acid isomers, and its structural formula is as follows:
Punicic acid mainly is present in the seed of pomegranate (Punica granatum) and snakegourd (Trichosanthes kirilowii), it is reported that contain 60 ~ 80% punicic acid in the granada seed oil, the content of different cultivars has difference.Therefore punicic acid is a kind of nontoxic, natural and orally active food composition.
Summary of the invention
The technical problem to be solved in the present invention provides a kind of punicic acid or punicic acid compound application method on the DHA content in improving body, adopts method of the present invention can improve the content of DHA in mammal and the human body.
In order to solve the problems of the technologies described above, the invention provides the application on the DHA content in improving body of a kind of punicic acid or punicic acid compound.
The improvement of the application on the DHA content in improving body as punicic acid of the present invention or punicic acid compound: be used to improve the DHA content in animal or human's body body.
The further improvement of the application on the DHA content in improving body as punicic acid of the present invention or punicic acid compound: the punicic acid compound is pomegranate acid esters, pomegranate hydrochlorate or punicic acid metabolin.
The further improvement of the application on the DHA content in improving body as punicic acid of the present invention or punicic acid compound: punicic acid is the trichosanthes kirilowii Maxim seed oil that contains the granada seed oil of punicic acid or contain punicic acid.
The further improvement of the application on the DHA content in improving body as punicic acid of the present invention or punicic acid compound:
With punicic acid or punicic acid compound with use after active material mixes;
Described active component is vitamin, aliphatic acid, phenolic acid class, flavonoids or polyphenoils.
The further improvement of the application on the DHA content in improving body as punicic acid of the present invention or punicic acid compound:
Aliphatic acid is n-3 polyunsaturated fatty acid, CLA, conjugated triene acid isomer body or conjugated triene acid complex;
The phenolic acid class is Tea Polyphenols or catechin;
Flavonoids is rutin or bamboo-leaves flavones.
The n-3 polyunsaturated fatty acid is leukotrienes, DHA and EPA.
Among the present invention, punicic acid or punicic acid compound can be used as nutritious supplementary pharmaceutical, to improve the content of the DHA in mammal and the human body.
Among the present invention, punicic acid or punicic acid compound can derive from the grease that granada seed oil, trichosanthes kirilowii Maxim seed oil etc. are rich in punicic acid, also can derive from chemical synthesis.
Among the present invention, punicic acid or punicic acid compound adopt oral form; Can take separately, also can be in feed or food, with forms such as grease carrier compounds.This food comprises functional food, animal feed, milk, newborn class, cereal foods, baby food, old people food etc.Among the present invention, punicic acid compound and a-tocopherol exist simultaneously.Among the present invention, punicic acid or punicic acid application of compound form can be by emulsion, soft gel, electuary, dairy products, microemulsion and edible oil.
The invention belongs to the method for DHA content in a kind of animal or human's of raising body body, this method comprises to the animal or human takes punicic acid or punicic acid compound, feeds to the animal or human with single dose or multiple dose, and the carrier of feeding can variation.Form that can the nutritional supplementation product is used punicic acid or punicic acid compound.The nutritional supplementation product comprises dairy products such as cereal foods, milk, sour milk, baby food, old formula food, body weight control product, sport nutrition formula food, beverage etc., low-carb food, diabetes patient's special food and relevant health product.Punicic acid or punicic acid compound can be made animal foodstuff and comprise feed for pet (cat grain, dog grain, other feed for pet etc.).
Instructions of taking of the present invention is oral; Consumption is punicic acid 0.15 ~ 3g/d, or granada seed oil 0.25 ~ 5 mL(punicic acid content is 60%) or granada seed oil 0.1875 ~ 3.75 mL (punicic acid content is 80%).
Remarks explanations: punicic acid content is 60% to be meant and to contain the 600g punicic acid in the 1000mL granada seed oil.All the other roughly the same.
Acceptable carrier of the present invention comprises capsule, soft capsule, tablet, emulsion etc., and with the supplement of soft capsule or form of hard gelatin capsules, its capsule filling can comprise a-tocopherol, edible gelatin, gel, starch, dextrin, starch derivatives.
The present invention has following advantage:
1. simply by taking punicic acid or granada seed oil or other are rich in the grease of punicic acid, can improve the content of the DHA in the body, can play anti-oxidantly, improve the effect of cognition etc.
2. the granada seed oil safety non-toxic is rich in punicic acid (60 ~ 80%), is a kind of new resources that well replenish DHA.Can take the mode of cold press to obtain fully (usual manner), get rid of the unsafe factor that organic solvent extracts.
3. granada seed oil is taked pomegranate leftover bits and pieces pomegranate seed to squeeze to obtain, can be a kind of good method that turns waste into wealth.
4. the elderly replenishes DHA mostly by picked-up fish oil or deep sea fish oil at present, but the absorption and the functions of expelling toxin of person in middle and old age's liver are relatively poor, can not well absorb and utilize DHA, and the punicic acid intake is few, and Transformation efficiency is up to 90 % in vivo above (many pieces of bibliographical informations).
5. extra punicic acid or the granada seed oil taken in outside normal diet do not cause harmful effect to liver and adipose tissue.There is not fat to drip generation.
Description of drawings
Below in conjunction with accompanying drawing the specific embodiment of the present invention is described in further detail.
Fig. 1 is the section comparison diagram of liver and fat.
The specific embodiment
Experiment 1,
Adopt the male ICR mouse in six ages in week, after adapting to 7 d, employing with add in the feed (conventional feed) forage feed that contains 1% punicic acid as experimental group (n=8), that is, in every kg feed, add the granada seed oil (punicic acid content is 80%) that contains the 10g punicic acid.Wherein in the control group diet, to replace granada seed oil with the isopyknic corn oil of granada seed oil.Free choice feeding, raised for 6 weeks after, put to death, get liver, kidney, heart and spleen etc. standby (being used for measuring the level of DHA content in the body).
After samples such as ICR mouse internal organ are carried out total fat-extraction, total fat is carried out esterification, the aliphatic acid that adopts GC to analyze ICR mouse internal organ is formed situation, and punicic acid metabolism situation in vivo.
Concrete experimental procedure is as follows:
1) extraction of total fat
A. extraction: according to people's such as Floch (1957) method with chloroform: methyl alcohol=2:1 extraction.Promptly get the 0.5g internal organ, place 20 mL test tubes, add 10 mL and contain 50 mg/L 2, the chloroform methanol solution of 6-BHT (BHT), fully mixing concussion, 4 ℃ of following lixiviate 24h.
B. filter: filtration will be extracted good sample, be filtered in the 100 ml separatory funnels.Former extraction test tube is used 5 ml chloroforms again: methyl alcohol=2:1 cleans, and changes separatory funnel over to; Clean with 5 ml chloroforms again, change separatory funnel over to.Remove filter paper, add 4 ml physiological saline again, and put into separatory funnel.The jog separatory funnel, and open the stopper venting, repeat, up to about air pressure balance.Concuss separatory funnel then.Separatory funnel left standstill about 4 hours, and two liquid levels separate fully.Collect lower floor's (chloroform layer) then to the round bottom evaporative flask.
C. concentrate: access lower floor's organic facies of separatory funnel with the round bottom evaporative flask, in 30 ℃ of water-baths, vacuumize rotary evaporation, wash three times to several limpid transparent oil-like extracts, at last the bottle lactone is transferred to the esterification pipe with 2 ml chloroforms.N2 dries up the organic reagent in the tool plug test tube.As can not in time measuring, can fill and be kept in-20 ℃ of environment behind the nitrogen to be measuredly, surveyed in two weeks.
2) esterification:
A, esterification: add 1 mL toluene and 3 mL sulfuric acid methanol solutions, tighten lid, under 70 ℃ of water bath condition, esterification 2 hours is shaken every 30 min and to be shaken up, and quickens esterification.
The extraction of b, methyl esters thing: after esterification is intact, add 2 ml n-hexanes, add physiological saline again, tighten lid, concuss 1 min, centrifugal 10 min of 2000 rpm to bottle mouth position.The upper strata n-hexane is placed with in the tip centrifuge tube of 2 ml distilled water in advance vibration with the careful sucking-off to of glass pipette.Again the upper strata is transferred to small amount of N a is housed in advance
2SO
4The tip centrifuge tube in.After the immigration of upper strata, if vibration gently is discovery Na wherein
2SO
4Can beat, prove that not having moisture to inhale comes.Again with in upper strata benzinum phase transfer to the tool plug test tube.
The purifying of c, methyl esters thing: with the quick SPE solid phase extraction column of crossing of n-hexane, again with the quick post of crossing of sample.With n-hexane cleaning tool plug test tube twice, all quick post of crossing.Slowly clean polyamide column with 5 % ether, liquid becomes to drip collects tool plug test tube.Earlier use chloroform: methyl alcohol is solution 2 ml of 2:1, cleans pillar at a slow speed with the 2ml n-hexane again.N2 dries up under 38 ℃ of water-baths.
3) gas phase (GC) chromatography
Again melt sample to sample bottle with 100 μ L n-hexanes, sample introduction 2 μ L are by the fatty acid composition of island functional activities of the body fluid chromatography (GC-2010 type) working sample.The analysis condition of gas-chromatography is: regulate air to 50, regulate hydrogen to 75.Regulate the Col(column temperature) to 160 ℃, regulate Det(monitor temperature) to 260 ℃, regulate the Aux(injector temperature) to 270 ℃.Column temperature heating schedule: 160 ℃ (0 min); 20 ℃/min, 180 ℃ (10 min); 20 ℃/min, 220 ℃ (5 min); 20 ℃/min, 230
℃ (16.5 min).
The component analyzing method of aliphatic acid is: adopt GC-2014 type gas chromatograph for determination aliphatic acid, V4.0 gathers spectrogram with the Hangzhou English spectrum scientific and technological development HS of Co., Ltd chromatographic data work station, and the spectral data gathered of Treatment Analysis.Chromatographic peak adopts the fatty acid methyl ester standard specimen that mixes, and (Nu-Chek-Prep Inc USA) identifies.Quantitative manner adopts area-method, and quantitative approach is a normalization method.
Statistical analysis technique adopts SPSS16.0 to analyze.It is variant on the statistics that outline value difference different (p＜0.05) is thought.
Result such as following table 1
Table 1
* expression has significant difference (p＜0.05)
According to the data of table 1 gained, we can draw to draw a conclusion: take in 1% punicic acid, can significantly improve the content of the DHA in liver, kidney, heart and the spleen.
Experiment 2
Adopt the SD rat in 4 ages in week, adapted to for 2 weeks after, be divided into 3 groups at random, 10 every group.Next 4 weeks, 3 groups of rats are irritated olive oil (mass concentration of punicic acid is 10%), olive oil and the water (group in contrast) to contain punicic acid every day respectively, and irritating stomach dosage is 0.5 mL/100g.The SD rat adopts the polycarbonate plastic cage to raise, and feeding environment keeps constant temperature (22 ± 1
oC), 12-h illumination and alternately dark, the free diet of all animals.Experiment finishes back (that is, irritating 4 week of stomach back), puts to death the SD rat, and fat, liver are used normal saline flushing behind the stomach wall that dissociates rapidly, and be to be measured.
Fat, liver section are fixed with the neutral formalin of 10% buffering behind the stomach wall, and FFPE is cut into 6 μ m thin slices then then, after the dyeing, carries out histological observation.Compare with control group, olive oil group and punicic acid group there is no significantly unusual; As shown in Figure 1.
After samples such as SD rat internal organ are carried out total fat-extraction, total fat is carried out esterification, the aliphatic acid that adopts GC to analyze SD rat internal organ is formed situation, and punicic acid metabolism situation in vivo.Statistical analysis technique adopts SPSS16.0 to analyze.It is variant on the statistics that outline value difference different (p＜0.05) is thought.Specifically as shown in table 2.
Table 2
| Liver fat acid (%) | Control group | The olive oil group | The punicic acid group |
| DHA | 9.44±0.49 | 9.01±0.85 | 13.00±1.58?* |
* expression has significant difference (p＜0.05)
At last, it is also to be noted that what more than enumerate only is several specific embodiments of the present invention.Obviously, the invention is not restricted to above embodiment, many distortion can also be arranged.All distortion that those of ordinary skill in the art can directly derive or associate from content disclosed by the invention all should be thought protection scope of the present invention.
Claims (7)
1. punicic acid or the punicic acid compound application on the DHA content in improving body.
2. punicic acid according to claim 1 or punicic acid compound be the application on the DHA content in improving body, it is characterized in that: be used to improve the DHA content in animal or human's body body.
3. punicic acid according to claim 2 or punicic acid compound be the application on the DHA content in improving body, and it is characterized in that: described punicic acid compound is pomegranate acid esters, pomegranate hydrochlorate or punicic acid metabolin.
4. punicic acid according to claim 2 or punicic acid compound be the application on the DHA content in improving body, and it is characterized in that: described punicic acid is the trichosanthes kirilowii Maxim seed oil that contains the granada seed oil of punicic acid or contain punicic acid.
5. according to claim 3 or 4 described punicic acids or the application on the DHA content in improving body of punicic acid compound, it is characterized in that: with punicic acid or punicic acid compound with use after active material mixes;
Described active component is vitamin, aliphatic acid, phenolic acid class, flavonoids or polyphenoils.
6. punicic acid according to claim 5 or punicic acid compound be the application on the DHA content in improving body, it is characterized in that:
Described aliphatic acid is n-3 polyunsaturated fatty acid, CLA, conjugated triene acid isomer body or conjugated triene acid complex;
Described phenolic acid class is Tea Polyphenols or catechin;
Described flavonoids is rutin or bamboo-leaves flavones.
7. punicic acid according to claim 6 or punicic acid compound be the application on the DHA content in improving body, and it is characterized in that: the n-3 polyunsaturated fatty acid is leukotrienes, DHA and EPA.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310137298.6A CN103211226B (en) | 2013-04-19 | 2013-04-19 | Punicic acid or the application of punicic acid compound in raising body in DHA content |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310137298.6A CN103211226B (en) | 2013-04-19 | 2013-04-19 | Punicic acid or the application of punicic acid compound in raising body in DHA content |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103211226A true CN103211226A (en) | 2013-07-24 |
| CN103211226B CN103211226B (en) | 2015-08-26 |
Family
ID=48809669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310137298.6A Expired - Fee Related CN103211226B (en) | 2013-04-19 | 2013-04-19 | Punicic acid or the application of punicic acid compound in raising body in DHA content |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103211226B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106822081A (en) * | 2016-12-30 | 2017-06-13 | 浙江海洋大学 | A kind of phosphatide type punicic acid fat or oil composition and its preparation method and application |
| CN107801867A (en) * | 2017-09-27 | 2018-03-16 | 浙江海洋大学 | A kind of large yellow croaker composite immune reinforcing agent and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101547615A (en) * | 2006-10-13 | 2009-09-30 | 热尔韦·达诺尼公司 | New composition for improving skin quality and a process for preparing the same |
| WO2010055300A2 (en) * | 2008-11-14 | 2010-05-20 | Aston University | Pomegranate oil |
| CN102342330A (en) * | 2011-08-25 | 2012-02-08 | 华南理工大学 | Oil and fat composition containing diglyceride and use thereof |
| CN102742660A (en) * | 2012-07-10 | 2012-10-24 | 陕西科技大学 | Goat milk tablet with effects of strengthening brain and regulating mind and preparation method thereof |
| US20130017286A1 (en) * | 2008-04-16 | 2013-01-17 | Mark Dreher | Pomegranate based skin protectant and topical application |
-
2013
- 2013-04-19 CN CN201310137298.6A patent/CN103211226B/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101547615A (en) * | 2006-10-13 | 2009-09-30 | 热尔韦·达诺尼公司 | New composition for improving skin quality and a process for preparing the same |
| US20130017286A1 (en) * | 2008-04-16 | 2013-01-17 | Mark Dreher | Pomegranate based skin protectant and topical application |
| WO2010055300A2 (en) * | 2008-11-14 | 2010-05-20 | Aston University | Pomegranate oil |
| CN102342330A (en) * | 2011-08-25 | 2012-02-08 | 华南理工大学 | Oil and fat composition containing diglyceride and use thereof |
| CN102742660A (en) * | 2012-07-10 | 2012-10-24 | 陕西科技大学 | Goat milk tablet with effects of strengthening brain and regulating mind and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| AFSANA YASMIN，等: ""Effect of conjugated linolenic acid (cis-9, trans-11, cis-13–18:3) on growth performance and lipid composition of fingerling rainbow trout Oncorhynchus mykiss"", 《FISHERIES SCIENCE》, vol. 70, no. 6, 31 December 2004 (2004-12-31), pages 1009 - 1018 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106822081A (en) * | 2016-12-30 | 2017-06-13 | 浙江海洋大学 | A kind of phosphatide type punicic acid fat or oil composition and its preparation method and application |
| CN107801867A (en) * | 2017-09-27 | 2018-03-16 | 浙江海洋大学 | A kind of large yellow croaker composite immune reinforcing agent and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103211226B (en) | 2015-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ibrahim et al. | Chemical composition, medicinal impacts and cultivation of camelina (Camelina sativa) | |
| CN102481325B (en) | Composition for preventing or treating obesity-related diseases mediated by the activation of ampk and including 2,5-bis-aryl-3,4-dimethyltetrahydrofuran lignans as active ingredients | |
| JP6335508B2 (en) | Growth hormone secretagogue | |
| CN106900885A (en) | A kind of microencapsulation peony seed oil, complex composition and preparation method thereof | |
| CN102058631B (en) | Seabuckthorn leaf extract preparation and preparation method thereof | |
| CN103211226B (en) | Punicic acid or the application of punicic acid compound in raising body in DHA content | |
| JP2013071909A (en) | Intracerebral lipid peroxide accumulation inhibitor | |
| CN109082381A (en) | Split the application of pot algae and its preparation in improving ruminant milk in DHA content | |
| JP6735224B2 (en) | Activator of glucose metabolism in astrocytes | |
| CN104351779B (en) | A kind of anemia of pregnant woman's compound recipe Oleum Camelliae and preparation method thereof | |
| JP6450317B2 (en) | Soft capsule containing DHA and EPA | |
| CN101185706A (en) | Hippophae rhamnoides nutrition mixture with delaying senility function and preparation technique thereof | |
| CN109077193A (en) | It splits pot algae and its preparation and is improving the application in laying rate of laying hen | |
| CN109527579A (en) | A kind of application of surprise Asia seed oil product and preparation method thereof and the sub- seed oil product of the surprise | |
| CN106727915B (en) | Composition for stably and efficiently improving memory and preparation method and application thereof | |
| JP2011057585A (en) | Antidepressant agent | |
| JP6063543B2 (en) | Preventive or ameliorating agent for overactive bladder | |
| CN1694693A (en) | Blood fluidity improving agent | |
| JP2013063941A (en) | Prophylactic or improving agent of irritable bowel syndrome | |
| CN108096299B (en) | Method for extracting and separating kiwi fruit seed active site and application thereof | |
| JP5897354B2 (en) | Preventive or ameliorating agent for overactive bladder | |
| US20230241149A1 (en) | Transthyretin tetramer stabilizing agent, and preventing agent or progression suppressing agent for transthyretin amyloidosis | |
| US20230241022A1 (en) | Transthyretin tetramer stabilizing agent, and preventing agent or progression suppressing agent for transthyretin amyloidosis | |
| Le Bao et al. | Effects of edible Terminalia catappa L. seed oil on physiological parameters of Mus musculus L mice | |
| JP7011400B2 (en) | Astrocyte glucose metabolism activator |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150826 Termination date: 20160419 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |